Business Context and Reporting Period
This Form 8-K filing by EyePoint Pharmaceuticals, Inc. (EYPT) was submitted on May 22, 2019, reporting events occurring on May 20, 2019. The filing addresses Item 5.02 regarding the departure of a senior officer and the appointment of a new principal accounting officer.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and personnel changes.
Material Changes
- Departure: Leonard S. Ross, Vice President of Finance and Chief Accounting Officer, will leave the company effective July 31, 2019.
- Appointment: David Price, the current Chief Financial Officer (since August 2018), will assume the role of principal accounting officer upon Mr. Ross's departure.
- Compensation: No new compensatory arrangements are being entered into with Mr. Price for this appointment.
Management Commentary and Background
Management highlights Mr. Price's extensive background, including over 25 years of experience in healthcare, investment banking, and accounting. His prior roles include CFO positions at Concordia International Corporation, Bioventus (where he led a $175 million debt financing and $210 million public debt raise), Cornerstone Therapeutics Inc., and EDGAR Online, Inc. He also served as a managing director at Jefferies & Company and Bear Stearns & Co.
Investor Verification Checklist
- Confirm the effective date of the leadership transition (July 31, 2019).
- Verify that no undisclosed compensatory agreements exist for the new principal accounting officer.
- Review subsequent filings for any impact on the company's financial reporting timeline due to the change in accounting leadership.